

## Q4 FY23 QUARTERLY ACTIVITIES REPORT & APPENDIX 4C

### Phase I clinical trial commencement & strong personal testing growth

**Microba Life Sciences Limited** (ASX: MAP) (“Microba” or the “Company”), a precision microbiome Company, is pleased to provide a summary of its activities for the quarter ended 30 June 2023.

#### Key Highlights

- The first agreement executed with Sonic Healthcare (ASX: SHL) to deliver Microba’s advanced infectious disease testing technology MetaPanel™ into Australia, announced following the end of the Quarter
- Strong growth in uptake of Microba’s next generation healthcare test, MetaXplore™, with 87% growth in tests sold between March and June
- Inflammatory Bowel Disease Program – MAP 315 Phase I trial commenced, transitioning the company to a clinical stage drug development company
- Immuno-Oncology Program – Multiple immunological experiments progressed
- Autoimmune Disease Program – Discovery program progressing on schedule
- Further advancement of the sector with FDA approval of Vowst the first oral microbiome therapeutic for Seres Therapeutics (NASDAQ: MRCB) in April 2023
- Q4 FY23 unaudited revenue totalled \$2.25m, up 21.5% yoy with Personal Testing up 35.5% to \$1.27m and Research Testing up 7.0% to \$0.98m
- FY23 unaudited revenue of \$5.42m, up 15.6% yoy with Personal Testing up 23.4% to \$3.07m and Research Testing up 6.7% to \$2.34m
- Q4 FY23 cash receipts totalling \$1.69m, representing 15.2% growth on the pcq
- FY23 cash receipts totalling \$6.33m, representing 37.5% growth on the prior year
- \$32.04 million in cash or equivalents as at 30 June 2023
- The Company will host an investor webinar with CEO Dr Luke Reid and SVP Therapeutics Prof. Trent Munro at 10:30am AEST on 27 July 2023.  
[Register here for the webinar](#)

#### Commenting on the quarter, Microba’s CEO, Dr Luke Reid, said:

*“Microba delivered another strong quarter of growth from our Personal Testing services. Signing the distribution agreement with Sonic Healthcare to take our advanced infectious disease test MetaPanel™ Australia-wide is the first step in our partnership with Sonic, and opens new markets which we believe could represent significant commercial opportunity for the Company. At the start of the financial year, the Company guidance was that revenue growth was expected to be weighted to the second half, and this was the case with 51% growth from H1 to H2 in FY23. Our Testing Services have finished the year in a robust position with a strong growth trajectory, 13 operational countries, and the first agreement executed from our major partnership with Sonic Healthcare.”*

*“For Microba’s therapeutics, the Phase I clinical trial commencement for our Inflammatory Bowel Disease program with lead candidate MAP 315, formally transitioned Microba into a clinical stage drug development company. This significant milestone encompasses many years of work, and demonstrates the drug development capability which has been established at Microba to progress novel microbiome drug candidates from discovery, guided by our data-driven platform, all the way through to an orally delivered drug product dosed in a first in human clinical trial. Through our therapeutic programs and pipeline of assets, I am excited about the impact we can have on individuals suffering from chronic diseases and the commercial opportunity for shareholders.”*

## Strong global revenue growth for Microba's global Testing Services

Execution of Microba's Testing Services strategy delivered positive revenue growth for Q4, up 21% yoy to \$2.25m. Last quarter it was stated that Q4 FY23 was expected to benefit from the recently launched MetaXplore™ testing range in Australia and further international growth, which was delivered during the quarter. During Q4 FY23, growth was principally driven by Microba's Personal Testing business up 35% yoy to \$1.27m, with growth in both domestic and international revenue. International Personal Testing revenue was up 51% yoy for the quarter driven by partners, including our partnership with Europe's largest medical diagnostics company SYNLAB. Domestic Personal Testing revenues were up 16% yoy for the quarter driven by growth in uptake of MetaXplore™ from healthcare professionals. This trajectory has set up a strong platform for continued growth in FY24.

## Continued growth in uptake of MetaXplore™ healthcare test with Australian healthcare professionals

Following the momentum from Microba's launch of the new MetaXplore™ test range last quarter, we saw strong growth in Q4:

- 87% growth in MetaXplore™ tests sold (March 23 vs June 23)
- 480% growth on previous quarter in registered healthcare professional accounts

A core component of Microba's Personal Testing growth strategy is to leverage the Company's world-leading technology and capability to advance the clinical application of microbiome testing to become embedded as a routine part of health and disease management. The MetaXplore™ test range was developed together with healthcare professionals and is expected to represent a large addressable market for Microba with >30% of the population suffering from a disorder of gut-brain interaction (DGBI) related to the bowel<sup>1</sup>, and >20% of the population estimated to suffer from a chronic health issue which may be influenced by their gut microbiome<sup>2</sup>. The MetaXplore™ test range through the Co-Biome™ brand can be accessed in Australia via a healthcare professional, and in FY24 is expected to be rolled out through Microba's international healthcare distribution partner network.

## First distribution agreement executed with Sonic Healthcare for Microba's advanced infectious disease test MetaPanel™

The first distribution agreement with Sonic Healthcare was signed to deliver Microba's advanced infectious disease testing technology MetaPanel™ Australia-wide through the Sonic Healthcare Australia Pathology network. The new metagenomic diagnostic test has been designed to identify a comprehensive panel of pathogenic microorganisms and genes to advance the standard of care in gastrointestinal infectious disease pathology. It is expected that this could represent a significant commercial opportunity for the company with an estimated initial target market of over 16 million patients<sup>3</sup> globally which are high-risk and susceptible to gastrointestinal infection, and receive routine testing for pathogens in a hospital setting. Further information will be shared on this product and the commercial opportunity over the coming quarters aligned to the launch of this product which is expected to occur in Q2 FY24. Microba continues to work actively with Sonic Healthcare to progress distribution arrangements across their major markets.

---

<sup>1</sup> Estimated based on the prevalence of specific Disorders of the Gut-Brain Interaction across 26 countries (Av prevalence of 32.8% DOI: [10.1111/nmo.14594](https://doi.org/10.1111/nmo.14594)), and the proportion regularly seeking medical support with one or more doctor visit per month (Average 15.4% - DOI: [10.1053/j.gastro.2020.04.014](https://doi.org/10.1053/j.gastro.2020.04.014))

<sup>2</sup> Estimated based on current literature on the understanding of the role of the microbiome in chronic disease (Vijay, Amrita, and Ana M. Valdes. (2022): 489-501. DOI: [10.1038/s41430-021-00991-6](https://doi.org/10.1038/s41430-021-00991-6)) and burden of these chronic diseases (Australian Bureau of Statistics (2020-21), [Health Conditions Prevalence](https://www.abs.gov.au/health-conditions-prevalence), ABS Website, accessed 20 March 2023.)

<sup>3</sup> Estimated based on the global number of immuno-compromised patients and other patients at high risk for gastrointestinal infection (>8.1m global and >68k Australian chemotherapy treated solid tumor cancer patients, and >1.1m global and >8k Australian haematological cancer patients DOI: [https://doi.org/10.1016/S1470-2045\(19\)30163-9](https://doi.org/10.1016/S1470-2045(19)30163-9) & <https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2021/summary>), (>3m global and 12k Australian dialysis patients DOI: [10.1038/s41581-022-00542-7](https://doi.org/10.1038/s41581-022-00542-7) & [https://www.anzdata.org.au/wp-content/uploads/2019/09/c04\\_haemodialysis\\_2018\\_ar2019\\_v2.0\\_2020619.pdf](https://www.anzdata.org.au/wp-content/uploads/2019/09/c04_haemodialysis_2018_ar2019_v2.0_2020619.pdf) & [https://www.anzdata.org.au/wp-content/uploads/2021/09/c05\\_peritoneal\\_2020\\_ar\\_2021\\_Chapter\\_v1.0\\_20220530\\_Final.pdf](https://www.anzdata.org.au/wp-content/uploads/2021/09/c05_peritoneal_2020_ar_2021_Chapter_v1.0_20220530_Final.pdf)), (>140k global and >1k Australian Organ Transplant patients per year <https://www.transplant-observatory.org/> & <https://www.health.gov.au/topics/organ-and-tissue-donation/organ-and-tissue-donation-in-australia>), (>3.5m global and >25k long stay ICU patients – estimate based on data from <https://ourworldindata.org/grapher/intensive-care-beds-per-100000> and other sources)

### Advancement in international distribution

Aligned to Microba's Personal Testing growth strategy, international expansion with the Company's leading bench of medical diagnostic and healthcare partners continues. In Q4 an agreement was executed with SYNLAB in Brazil, providing Microba with access into the largest country in South America. Overall in Q4, progress was made across multiple partners and countries delivering 51% revenue growth yoy from international partnerships.

During FY23, the Company planned to double the country distribution base from 4 to 8. At the close of the financial year, Microba significantly exceeded its plan with 14 countries contracted and 13 of those countries now operational with first sales delivered.

Together, Sonic Healthcare, SYNLAB, Genova Diagnostics and G42 Healthcare provide Microba with strong access into major global healthcare markets across the globe:

- Sonic Healthcare > UK, Germany, Switzerland, Belgium, Australia, NZ & US
- SYNLAB > Broader Europe & LATAM
- Genova Diagnostics > US
- G42 Healthcare > Middle East (GCC Region)

With access to 35 countries through this network and active operations now in 13, the Company has an excellent foundation for growth. The team is executing diligently to progressively move partners through Microba's partner success program to contract, operationalise, activate sales and marketing, and support the growth of these partners to provide Microba-powered testing to their customers. During Q4 Italy and Romania advanced from sales and marketing activation to execution and growth. The below table summarises the current stage of Microba's distribution partners.

Stage	Countries & Partners
Planning & Contracting	21 countries (Including Sonic Healthcare companies)
Operationalisation	United States (LUM), Brazil (SYAB), Australia (SHL)
Sales & Marketing Activation	Australia (MH), United Arab Emirates (G42), Portugal (SYAB), Czech Republic (SYAB), Türkiye (SYAB), Poland (SYAB), Croatia (SYAB), Hungary (SYAB), United States (GEN)
Execution & Growth	Australia (MAP), Australia (MG), New Zealand (MG), Spain (SYAB), Italy (SYAB), Romania (SYAB)

SHL = Sonic Healthcare, SYAB = SYNLAB affiliate organisation, G42 = G42 Healthcare, GEN = Genova, LUM = Luminary Health Centers, MH = Midnight Health, MG = Metagenics, MAP = Microba

### Inflammatory Bowel Disease Program – Phase I commenced and progressing on schedule

At the end of the quarter, the Phase I clinical trial of lead candidate MAP 315 commenced with first patients dosed. The trial is progressing to schedule with dosing completed for 50% of participants and recruitment on track for the remainder of the study.

MAP 315 is being developed for the treatment of Ulcerative Colitis, a debilitating form of Inflammatory Bowel Disease (IBD) with >50% of patients unable to achieve sustained remission with current standard of care. The market for ulcerative colitis treatment was valued at US\$7.5b in 2020 and is forecast to grow to US\$10.8b by 2030<sup>4</sup>.

Over the quarter, manufacturing of MAP 315 was completed with Bacthera in Europe and all activities finalised to dose first patients in the Phase I trial of MAP 315. The Phase I trial is a randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of MAP 315 in healthy adults. The trial involves 32 healthy participants and is being conducted by Nucleus Network, utilising their world-class clinical trial facilities in Melbourne.

Inflammatory Bowel Disease is a term for conditions that cause prolonged inflammation of the digestive tract and now

<sup>4</sup> <https://www.nature.com/articles/d41573-021-00194-5>, <https://www.alliedmarketresearch.com/ulcerative-colitis-market>

affects more than 7 million people globally, with this number increasing each year<sup>5</sup>. Ulcerative colitis (UC) is one of the two major forms of IBD which results in inflammation and ulcers (sores) in the digestive tract, causing a debilitating chronic condition. Patients are currently treated with anti-inflammatory and immunomodulatory medication to dampen the disease and control symptoms, often with significant side effects. These available treatment options commonly fail, with more than 50% of patients unable to achieve sustained remission<sup>6</sup>, which sees them experiencing regular episodes of inflammation, diarrhoea, bleeding and abdominal pain<sup>7</sup>. As many as 25% of patients require hospitalisation<sup>8</sup>.

Microba's novel drug candidate MAP 315 was originally identified using the Company's data-driven Therapeutic Platform, demonstrating that this previously unidentified novel bacterial species is commonly observed in healthy individuals but consistently deficient in individuals with Inflammatory Bowel Disease, and in particular Ulcerative Colitis. Subsequent pre-clinical investigation of MAP 315 through both *in vitro* and *in vivo* models demonstrated that MAP 315 promotes epithelial restitution and mucosal healing – biological activities that are associated with disease remission but not adequately addressed through existing therapy. MAP 315 provides a compelling commercial opportunity to fill a key gap in the current standard of care for Ulcerative Colitis treatment and represents a potential novel treatment paradigm for patients living with this debilitating disease.

To date, 10 of the top 20 major pharmaceutical companies have invested in microbiome drug development programs. There is increasing attention on the sector with the recent FDA approval of Rebyota, the first ever FDA approved fecal microbiota product from Ferring Pharmaceuticals in November 2022, and FDA approval of Vowst the first oral microbiome therapeutic for Seres Therapeutics (NASDAQ: MRCB) which occurred during the quarter in April 2023.

#### **Immuno-Oncology Program – Pre-clinical activities progressing on schedule**

During the quarter, Microba's Immuno-Oncology Program progressed multiple immunological experiments, including animal model studies with results expected to be delivered across Q1 & Q2 FY24. This program is targeting the development of a therapeutic to improve response rates in cancer patients receiving immune checkpoint inhibitor (ICI) therapy. Global immune checkpoint inhibitor sales continue to grow, with Merck announcing sales of the market-leading drug Keytruda of US\$20.9b for calendar year 2022<sup>9</sup>.

Microba's first animal model study which completed in Q3, assessed Microba's therapeutic leads in a refractory mouse model of melanoma, one of the most common forms of cancer with a large number of annual deaths. The results demonstrated a significant reduction in tumour volume for mice treated with an immune checkpoint inhibitor (ICI) together with Microba's therapeutic leads, when compared to control mice that received ICI therapy alone. These first results supported an accelerated program of work which is currently underway elucidating the mechanism of action to enable lead selection and a clinical study in patients.

While there have been considerable advances in the treatment options for melanoma, improvement of overall response rates and survival remain meaningful areas of opportunity. Furthermore, ICIs are used in a range of cancers beyond melanoma including lung, head and neck, breast, colon, cervical, and other types of cancer. With the ICI market being valued at over US\$30b with a >15% CAGR<sup>10</sup>, a microbiome-based adjuvant therapy that increases response to these drugs has the potential to become standard of care across a range of cancers, and therefore represents a substantial commercial opportunity for Microba.

There is an increasing body of literature supporting a key role for the microbiome in cancer<sup>11</sup>. Cancer immunotherapy, and more specifically ICIs have become standard of care for a range of tumour types. However, despite their impact on cancer

---

<sup>5</sup> [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(19\)30333-4/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30333-4/fulltext)

<sup>6</sup> <https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf>

<sup>7</sup> Scribano, M.L. Adverse events of IBD therapies. *Inflamm Bowel Dis.* (2008). <https://doi.org/10.1002/ibd.20702>.

<sup>8</sup> Pola, S. et al. Strategies for the care of adults hospitalized for active ulcerative colitis. *Clin Gastroenterol Hepatol.* (2012). <https://doi.org/10.1016/j.cgh.2012.07.006>.

<sup>9</sup> <https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2022-financial-results/>

<sup>10</sup> <https://au.finance.yahoo.com/news/immune-checkpoint-inhibitors-market-predicted-090000312.html>

<sup>11</sup> Sepich-Poore et al. (2021). *The microbiome and human cancer*. DOI: 10.1126/science.abc4552.

treatment, up to 70% of patients do not respond to these drugs<sup>12,13</sup> leaving a large, underserved patient population. Differences in the microbiomes of responders and non-responders to ICI treatment have been observed in international studies, and treatment of the microbiome using fecal microbiome transplants has demonstrated the ability to turn ICI non-responders into responders<sup>14,15</sup>. This presents an important opportunity for Microba to leverage its proprietary Therapeutics Platform to identify the key components of the microbiome which drive that effect and develop an effective adjuvant therapy to improve ICI response. In addition to the potential large commercial opportunity for this program, these results provide another validation of Microba's unique ability to discover therapeutically active biology from the human microbiome through the Company's platform.

#### **Autoimmune Disease Program – Discovery program progressing on schedule**

The autoimmune disease discovery program with partner Ginkgo Bioworks (NYSE: DNA) continues to progress on schedule with completion of Stage 1 activity screening scheduled as the next milestone for this program expected in Q2 FY24.

Overall, this 2-year program is tracking positively to deeply characterise a large number of bacteria from Microba's biobank which were identified using the company's data driven approach, to deliver therapeutic leads for multiple autoimmune diseases which represents a significant commercial opportunity for the company. The combination of Microba's unique ability to identify and isolate human gut bacteria associated with health together with the high-throughput microbial screening capabilities of Ginkgo Bioworks has created a powerful drug discovery workflow. In Q3 FY23, first results across multiple *in vitro* assays were delivered identifying leads with anti-inflammatory activity, effects on gene transcription associated with immune modulation, and other biological mechanisms of relevance to autoimmune and other chronic diseases.

Microba's Autoimmune Disease program was established in partnership with Ginkgo Bioworks (NYSE: DNA) in FY22 following their strategic investment into Microba's IPO, and embodies a 2-year discovery program principally targeting three autoimmune disorders (lupus, psoriatic arthritis and autoimmune liver diseases).

Autoimmune diseases are a family of more than 80 chronic and often life-threatening illnesses, which occur when the body's own immune system attacks the body's healthy cells, tissues and organs. Autoimmune conditions now impact around 5% of the population and their prevalence is rising<sup>16</sup>. In recent years, several studies have highlighted the role of the microbiome in the pathogenesis of autoimmune diseases<sup>17</sup>. The global market for autoimmune disease treatments was estimated to be US\$53.2b in 2019 and forecast to grow to US\$90.7b by 2024<sup>18</sup>. This program has the potential to generate multiple therapeutic assets for major unmet needs in the management of autoimmune diseases.

#### **Financial Update**

Unaudited revenue for the June 2023 quarter totalled \$2.25m, representing 21.5% growth on the prior corresponding period with Personal Testing up 35.5% to \$1.27m and Research Services up 7.0% to \$0.98m. Unaudited revenue for the full financial year totalled \$5.42m up 15.6% on the prior year with Personal Testing up 23.4% to \$3.07m and Research Services up 6.7% to \$2.34m. Cash receipts for the June 2023 quarter totalled \$1.69m representing 15.2% growth on the prior corresponding period and cash receipts for the full financial year totalled \$6.33m, representing 37.5% growth on the prior corresponding period.

As at 30 June 2023, Microba had \$32.04 million in cash or equivalents. During the quarter the company invested \$1.28m into the advancement of its data driven drug discovery programs (Inflammatory Bowel Disease, Immuno-oncology, and Autoimmune Disease). Microba remains in a strong position to execute its growth strategy including a robust runway to

---

<sup>12</sup> Leonardi et al. (2020). *International Journal of Oncology*. DOI: 10.3892/ijo.2020.5088

<sup>13</sup> Wolchok et al. (2017). *New England Journal of Medicine*. DOI: 10.1056/NEJMoa1709684

<sup>14</sup> Baruch et al. (2020). *Science*. DOI: 10.1126/science.abb5920

<sup>15</sup> Davar et al. (2021). *Science*. DOI: 10.1126/science.abf3363

<sup>16</sup> Fugger, L et al. Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. *Cell*. (2020).

<https://doi.org/10.1016/j.cell.2020.03.007><https://doi.org/10.1016/j.cell.2020.03.007>

<sup>17</sup> De Luca, F. and Shoenfeld, Y. The microbiome in autoimmune diseases. *Clin Exp Immunol*. (2019). <https://doi.org/10.1111/cei.13158>.

<sup>18</sup> BCC Research. Autoimmune Disorder Therapies: Global Markets (2020).

progress the Company's therapeutic programs to key milestones.

In accordance with Listing Rule 4.7C, payments made during the quarter to related parties and their associates included in item 6.1 of Appendix 4C was \$119,500 and included Director fees.

#### Investor Webinar

The Company will host an investor webinar with CEO Dr Luke Reid and SVP, Therapeutics Prof. Trent Munro today at 10:30am AEST Thursday, 27 July 2023.

To register for the session and for more information click on the below link:

[Microba Q4 FY23 Investor Webinar Registration](#)

Investors can submit questions prior to the webinar to [simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au) or do so via the Q&A functions on Zoom.

#### Use of Funds

In section 7.4 of the Microba Life Sciences Prospectus, the Company provided a proposed use of funds statement for 24 months from listing. The table below only shows use of funds from IPO to the end of the most recent quarter ended 30 June 2023.

Use of Funds	Q4 FY23	Prior Total	Total Expenditure	Prospectus
Global market penetration and sales growth	1,300	4,657	5,957	7,200
Data driven drug discovery	1,285	7,659	8,944	13,100
Platform technology advancement	270	986	1,256	2,500
Administrative and working capital	546	3,797	4,343	4,700
Costs of the offer	-	2,429	2,429	2,500
Further capital raised – Sonic Healthcare	-	17,237	-	-
<b>Total</b>	<b>3,401</b>	<b>19,529</b>	<b>22,929</b>	<b>30,000</b>

During the three-month period ended June 2023, overall expenditure remained in line with the estimated use of funds as set out in the Prospectus.



*This announcement has been authorised for release by the Board.*

For further information, please contact:

**Dr Luke Reid**

Chief Executive Officer

E: [Luke.Reid@microba.com](mailto:Luke.Reid@microba.com)

**Simon Hinsley**

Investor / Media Relations

E: [simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)

T: +61 401 809 65

**About Microba Life Sciences Limited**

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

**For more information visit: [www.microba.com](http://www.microba.com)**

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group, whose contact information is housed on the Investor Relations page of the Company's website.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Microba Life Sciences Limited, and controlled entities

**ABN**

82 617 096 652

**Quarter ended ("current quarter")**

30 June 2023

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	1,690	6,338
1.2 Payments for		
(a) research and development	(1,003)	(8,147)
(b) product manufacturing and operating costs	(328)	(2,263)
(c) advertising and marketing	(368)	(1,305)
(d) leased assets	(151)	(595)
(e) staff costs	(1,823)	(7,241)
(f) administration and corporate costs	(1,364)	(3,563)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	441	800
1.5 Interest and other costs of finance paid	(6)	(17)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	68	2,790
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(2,844)</b>	<b>(13,203)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(291)	(475)
(d) investments	-	-
(e) intellectual property	(600)	(2,473)
(f) other non-current assets	-	-



Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(891)</b>	<b>(2,948)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	17,833
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(596)
3.5	Proceeds from borrowings	479	479
3.6	Repayment of borrowings	(144)	(480)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>335</b>	<b>17,236</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	35,397	30,581
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,844)	(13,203)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(891)	(2,948)

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	335	17,236
4.5	Effect of movement in exchange rates on cash held	47	378
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>32,044</b>	<b>32,044</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	30,902	34,277
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other – Restricted Cash*	1,142	1,120
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>32,044</b>	<b>35,397</b>

\*Relates to cash held in a Microba escrow account for the purposes of satisfying the Ginkgo Bioworks R&D activities under the agreement between Ginkgo and Microba. The balance is expected to be paid out within 12 months, and is current.

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(120)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>7. Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	(335)	(335)
<b>7.4 Total financing facilities</b>	<b>(335)</b>	<b>(335)</b>
<b>7.5 Unused financing facilities available at quarter end</b>		<b>0</b>
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
An unsecured insurance premium funding arrangement was entered into to finance the Group's annual insurance premiums. The balance originally drawn was \$479k, the balance at quarter end was \$335k, and is repayable over 11 equal monthly instalments, with a fixed interest rate of 3.89%.		

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(2,844)
8.2 Cash and cash equivalents at quarter end (item 4.6)	32,044
8.3 Unused finance facilities available at quarter end (item 7.5)	-
<b>8.4 Total available funding (item 8.2 + item 8.3)</b>	<b>32,044</b>
<b>8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	<b>11.3</b>
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	N/A
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	N/A
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	N/A
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **27 July 2023**

Authorised by: **The Board of Directors**

(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.